The University of Southampton
University of Southampton Institutional Repository

Effect of antidiabetic drug classes on the risk of liver-related events in individuals with T2D and MASLD

Effect of antidiabetic drug classes on the risk of liver-related events in individuals with T2D and MASLD
Effect of antidiabetic drug classes on the risk of liver-related events in individuals with T2D and MASLD
Background: we investigated the use of type 2 diabetes (T2D) medications, including pioglitazone, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors, in individuals with T2D and metabolic dysfunction–associated steatotic liver disease (MASLD), and explored the effect of these medications on long-term risk of liver-related events (LREs) and progression of liver stiffness in a retrospective cohort study.

Methods: we enrolled 7867 individuals with T2D and MASLD from 16 tertiary referral centers between February 2004 and January 2023. We recorded the use of pioglitazone, GLP-1RAs, and SGLT-2 inhibitors and analyzed the effects of these antihyperglycemic medications on the risk of developing incident LREs and the progression of liver stiffness over a median of 5.1 years of follow-up.

Results: pioglitazone, GLP-1RAs and SGLT-2 inhibitors were prescribed to 1238 (15.7%), 863 (11.0%), and 2386 (30.3%) individuals with T2D and MASLD, respectively. A significant increase in the utilization of GLP-1RAs and SGLT-2 inhibitors was observed from 2010–2017 to 2017–2023, with pioglitazone and SGLT-2 inhibitors being prescribed more frequently in Asian countries than in Western countries (pioglitazone: 17.9% vs 3.8%; SGLT-2 inhibitors: 34.4% vs 7.3%; P < .001). After propensity score matching, in competing risk models, SGLT-2 inhibitor use was significantly associated with a lower risk of developing both LREs (subdistribution hazard ratio, 0.23; 95% confidence interval, 0.08–0.69, P = .009) and liver stiffness progression (hazard ratio, 0.54; 95% confidence interval, 0.35–0.86, P = .008) after adjusting for potential confounders.

Conclusions: SGLT-2 inhibitor use is more prevalent among Asian than Western individuals. SGLT-2 inhibitors are associated with a lower risk of LREs in individuals with T2D and MASLD.
1542-3565
Shi, Yu
eed61b06-3d0a-4cdc-a0fb-9ad6687c36df
Kim, Seung Up
a59d694a-163b-49e5-813e-8b64b4e46c56
Yip, Terry Cheuk-Fung
8f458b7d-01fd-40bc-be0d-17ff74fd8fde
Tsochatzis, Emmanuel
e6463ccf-1f18-45c2-bed5-1e463df255ce
Byrne, Chris
1370b997-cead-4229-83a7-53301ed2a43c
VCTE-Prognosis Study Group
et al.
Shi, Yu
eed61b06-3d0a-4cdc-a0fb-9ad6687c36df
Kim, Seung Up
a59d694a-163b-49e5-813e-8b64b4e46c56
Yip, Terry Cheuk-Fung
8f458b7d-01fd-40bc-be0d-17ff74fd8fde
Tsochatzis, Emmanuel
e6463ccf-1f18-45c2-bed5-1e463df255ce
Byrne, Chris
1370b997-cead-4229-83a7-53301ed2a43c

Shi, Yu, Kim, Seung Up, Yip, Terry Cheuk-Fung and Tsochatzis, Emmanuel , VCTE-Prognosis Study Group and et al. (2025) Effect of antidiabetic drug classes on the risk of liver-related events in individuals with T2D and MASLD. Clinical Gastroenterology and Hepatology. (doi:10.1016/j.cgh.2025.06.001).

Record type: Article

Abstract

Background: we investigated the use of type 2 diabetes (T2D) medications, including pioglitazone, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors, in individuals with T2D and metabolic dysfunction–associated steatotic liver disease (MASLD), and explored the effect of these medications on long-term risk of liver-related events (LREs) and progression of liver stiffness in a retrospective cohort study.

Methods: we enrolled 7867 individuals with T2D and MASLD from 16 tertiary referral centers between February 2004 and January 2023. We recorded the use of pioglitazone, GLP-1RAs, and SGLT-2 inhibitors and analyzed the effects of these antihyperglycemic medications on the risk of developing incident LREs and the progression of liver stiffness over a median of 5.1 years of follow-up.

Results: pioglitazone, GLP-1RAs and SGLT-2 inhibitors were prescribed to 1238 (15.7%), 863 (11.0%), and 2386 (30.3%) individuals with T2D and MASLD, respectively. A significant increase in the utilization of GLP-1RAs and SGLT-2 inhibitors was observed from 2010–2017 to 2017–2023, with pioglitazone and SGLT-2 inhibitors being prescribed more frequently in Asian countries than in Western countries (pioglitazone: 17.9% vs 3.8%; SGLT-2 inhibitors: 34.4% vs 7.3%; P < .001). After propensity score matching, in competing risk models, SGLT-2 inhibitor use was significantly associated with a lower risk of developing both LREs (subdistribution hazard ratio, 0.23; 95% confidence interval, 0.08–0.69, P = .009) and liver stiffness progression (hazard ratio, 0.54; 95% confidence interval, 0.35–0.86, P = .008) after adjusting for potential confounders.

Conclusions: SGLT-2 inhibitor use is more prevalent among Asian than Western individuals. SGLT-2 inhibitors are associated with a lower risk of LREs in individuals with T2D and MASLD.

Text
Revised_Main Text - Accepted Manuscript
Restricted to Repository staff only until 7 June 2026.
Request a copy
Text
Revised_Supplemtary information - Accepted Manuscript
Restricted to Repository staff only until 7 June 2026.
Request a copy
Text
Figure 1 - Accepted Manuscript
Restricted to Repository staff only until 7 June 2026.
Request a copy
Text
Figure 2 - Accepted Manuscript
Restricted to Repository staff only until 7 June 2026.
Request a copy
Text
Figure 3 - Accepted Manuscript
Restricted to Repository staff only until 7 June 2026.
Request a copy
Text
Revised_graphical abstract - Accepted Manuscript
Restricted to Repository staff only until 7 June 2026.
Request a copy

Show all 6 downloads.

More information

Accepted/In Press date: 7 June 2025
e-pub ahead of print date: 7 June 2025

Identifiers

Local EPrints ID: 505500
URI: http://eprints.soton.ac.uk/id/eprint/505500
ISSN: 1542-3565
PURE UUID: af5a35fe-5109-48f8-b14a-36de5124ab2c
ORCID for Chris Byrne: ORCID iD orcid.org/0000-0001-6322-7753

Catalogue record

Date deposited: 10 Oct 2025 16:38
Last modified: 11 Oct 2025 01:40

Export record

Altmetrics

Contributors

Author: Yu Shi
Author: Seung Up Kim
Author: Terry Cheuk-Fung Yip
Author: Emmanuel Tsochatzis
Author: Chris Byrne ORCID iD
Corporate Author: VCTE-Prognosis Study Group
Corporate Author: et al.

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×